FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy

statnews.com/2025/07/11/fda-rejects-capricors-cell-therapy-for-duchenne-muscular-dystrophy

The Food and Drug Administration rejected a marketing application from Capricor Therapeutics for a cell therapy to treat Duchenne muscular dystrophy, the company said Friday.
In its letter to Capricor, the FDA said the company’s application “does not meet the statutory requirement for…

This story appeared on statnews.com, 2025-07-11 16:44:18.494000.
The Entire Business World on a Single Page. Free to Use →